Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier
The incidence of brain metastases has been increasing constantly for the last 20 years, because of better control of metastases outside the brain, and the failure of most drugs to cross the blood–brain barrier at relevant pharmacological concentrations. Recent advances in the molecular biology of ca...
Main Authors: | Eurydice Angeli, Guilhem Bousquet |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/9/1446 |
Similar Items
-
The Pharmacology of Xenobiotics after Intracerebro Spinal Fluid Administration: Implications for the Treatment of Brain Tumors
by: Justine Paris, et al.
Published: (2021-01-01) -
Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
by: Lu YY, et al.
Published: (2016-03-01) -
Clinical Experience with First-generation Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients
with Brain Metastasis
by: Huixing DONG, et al.
Published: (2017-02-01) -
Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
by: Yuhan Zhang, et al.
Published: (2021-09-01) -
Complete Remission of Brain Metastases in Non-Small Cell Lung Cancer Patients Harboring an EGFR Mutation Treated with Tyrosine Kinase Inhibitor without Radiotherapy: A Report of 3 Cases
by: Yun Hwa Jung, et al.
Published: (2014-03-01)